Overactive Bladder Syndrome
111
10
11
48
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
7.2%
8 terminated out of 111 trials
85.7%
-0.9% vs benchmark
29%
32 trials in Phase 3/4
21%
10 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 48 completed trials
Clinical Trials (111)
INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder
Efficacy and Safety of Peroneal Electric Transcutaneous Neuromodulation in the Real-world Clinical Practice
Moving Beyond p-Values: MCID for OAB-V8 8 and ICIQ-SF in Patients With OAB
Yoga for Treatment of Overactive Bladder in Pediatric Patients
Cyclic Versus Continuous Sacral Neuromodulation for LUTS
Improving Overactive Bladder Treatment Access and Adherence
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Impact of TTNS on Bladder Symptoms Among People With MS, A RCT
Real-world Experiences and Voices Exploring the Actual Lived Burden of OAB: A Mixed-methods Multi-country PROMs Study on OAB Patients' Quality of Life
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RCT on Multimodal Self-treatment for Women With Incontinence Using a Digital Health Application
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
rTMS in Overactive Bladder
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study
Role of Combination Therapy in Women With Refractory Overactive Bladder
Oxybutynin for Post-surgical Bladder Pain and Urgency
Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.